Detalhe da pesquisa
1.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 170(6): 1109-1119.e10, 2017 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28886381
2.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 174(4): 1031-1032, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30096300
3.
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Cancer
; 130(12): 2191-2204, 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38376917
4.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524096
5.
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
J Natl Compr Canc Netw
; 22(1D): e240002, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244274
6.
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Int J Mol Sci
; 25(4)2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396800
7.
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
J Transl Med
; 21(1): 275, 2023 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37087493
8.
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
J Transl Med
; 21(1): 265, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072748
9.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
J Transl Med
; 21(1): 508, 2023 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507765
10.
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
J Transl Med
; 21(1): 488, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37475035
11.
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(11): 1181-1203, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935106
12.
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
J Transl Med
; 20(1): 179, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449104
13.
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
J Transl Med
; 20(1): 200, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538491
14.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
J Transl Med
; 20(1): 391, 2022 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36058945
15.
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
J Transl Med
; 20(1): 257, 2022 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672823
16.
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Invest New Drugs
; 40(5): 1051-1065, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35635631
17.
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Future Oncol
; 18(12): 1449-1459, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040698
18.
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Lancet Oncol
; 22(12): 1692-1704, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774225
19.
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
N Engl J Med
; 379(8): 722-730, 2018 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30134131
20.
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
J Transl Med
; 19(1): 144, 2021 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827609